secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIODESIX INC (BDSX)
CIK:        0001439725
Form:       8-K
Filed at:   2025-03-03T23:59:59+00:00
Accession:  0000950170-25-030814
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biodesix FY2024 revenue $71.3M (+45% YoY); guides FY2025 $92-95M
----------------------------------------------------------------

- FY2024 total revenue $71.3M, up 45% YoY; gross margin 78%, up 5 pts from FY2023.
- Lung Diagnostic testing revenue $64.7M (+43% YoY); Biopharma Services $6.6M (+70% YoY).
- Net loss $42.9M improved 18%; adjusted EBITDA loss $22.1M improved 32% vs FY2023.
- Cash $26.2M at Dec 31, 2024; post-quarter amended term loan to extend $10M Tranche C availability.
- FY2025 total revenue guidance $92-95M, representing 29-33% growth over FY2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1439725/000095017025030814/0000950170-25-030814-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1439725/000095017025030814/bdsx-20250303.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-030814

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer